Mylan (NASDAQ: MYL), a global pharmaceutical company, has voluntarily waived its exclusive rights to distribute its generic version of Kaletra (lopinavir/ritonavir) antiretroviral 100mg/25mg and 200mg/50mg tablets in the United States, it was reported on Wednesday.
This move is intended to help increase the available supply of the product should it prove effective in the treatment of coronavirus. It will allow the company to enable other generic applicants to be eligible for FDA approval of their medicines for patients in the United States, expanding access in the event that additional clinical studies or other evaluations conclude that the product may be effective in treating COVID-19.
The company was the first to file a substantially complete abbreviated new drug application with the Food and Drug Administration (FDA) to launch a generic version of this product to market, entitling the company to a 180-day marketing exclusivity period upon final FDA approval, which is pending.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US